Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.

about

The Active Components of Fuzheng Huayu Formula and Their Potential Mechanism of Action in Inhibiting the Hepatic Stellate Cells Viability - A Network Pharmacology and Transcriptomics Approach.

P2860

Q55270064-D40F4789-36F1-4BE4-8FF2-5BB287704BF1

P2860

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.

Item

http://www.wikidata.org/entity/Q49819768

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dual PPARα/γ agonist saroglita ...... y in experimental NASH models.

@en

Dual PPARα/γ agonist saroglita ...... y in experimental NASH models.

@nl

type

Item

label

Dual PPARα/γ agonist saroglita ...... y in experimental NASH models.

@en

Dual PPARα/γ agonist saroglita ...... y in experimental NASH models.

@nl

prefLabel

Dual PPARα/γ agonist saroglita ...... y in experimental NASH models.

@en

Dual PPARα/γ agonist saroglita ...... y in experimental NASH models.

@nl

P1476

Dual PPARα/γ agonist saroglita ...... y in experimental NASH models.

@en

P2093

Akshyaya Rath

http://www.w3.org/2001/XMLSchema#string

Bibhuti Bhoi

http://www.w3.org/2001/XMLSchema#string

Chitrang Trivedi

http://www.w3.org/2001/XMLSchema#string

Eshani Karmakar

http://www.w3.org/2001/XMLSchema#string

Hiren Patel

http://www.w3.org/2001/XMLSchema#string

Mukul R Jain

http://www.w3.org/2001/XMLSchema#string

Nabanita Das

http://www.w3.org/2001/XMLSchema#string

Pankaj R Patel

http://www.w3.org/2001/XMLSchema#string

Prabodha Swain

http://www.w3.org/2001/XMLSchema#string

Ramchandra Ranvir

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)

Role of mitochondria in nonalcoholic fatty liver disease

Peroxisome proliferator-activated receptors: nuclear control of metabolism

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation.

Adipose tissue as a buffer for daily lipid flux.

Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models.

GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation

P304

1084-1094

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LIV.13634

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29164820

http://www.w3.org/2001/XMLSchema#string

P932

6001453

http://www.w3.org/2001/XMLSchema#string

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.

about

P2860

P2860

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932